![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Emergent Looks to Chimerix for New Start Following Vaccine Contamination Scandal
Emergent Looks to Chimerix for New Start Following Vaccine Contamination Scandal
Emergent Biosolutions is purchasing exclusive rights to Chimerix’s antiviral drug Tembexa (brincidofovir) for $225 million up-front plus up to $100 million in potential milestone payments.
Chimerix is currently in negotiations with the U.S. government over a procurement contract for Tembexa, which gained the FDA’s approval in June 2021 in tablet and oral suspension formulations for treatment of smallpox.
Emergent said the licensing deal is a part of its growth plan through 2024, as the company seeks to recover from numerous setbacks for its COVID-19 vaccine production for Johnson & Johnson and AstraZeneca.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct